Free Trial

Adial Pharmaceuticals 8/13/2024 Earnings Report

Adial Pharmaceuticals logo
$0.97 +0.01 (+1.30%)
As of 04:00 PM Eastern

Adial Pharmaceuticals EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.39
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

Adial Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adial Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Adial Pharmaceuticals Earnings Headlines

Adial granted U.S. patent for treatment of alcohol, drug dependence
Mode Mobile is poised for massive growth and looking to disrupt the $1T+ smartphone industry - Invest Today
While other cell phone carriers are always looking for ways to squeeze every last penny out of their customers, my company pays users for the 40 hours a week they are using smartphone apps, listening to music, and watching videos online with their phones. And you can join us for just $0.26 per share. Plus, when you invest now, you can get up to 100% bonus shares!
Adial Pharmaceuticals Advances AD04 with Promising Study Results
See More Adial Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email.

About Adial Pharmaceuticals

Adial Pharmaceuticals (NASDAQ:ADIL), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

View Adial Pharmaceuticals Profile

More Earnings Resources from MarketBeat